SG11202112926YA - Engineering the hinge region to drive antibody dimerization - Google Patents

Engineering the hinge region to drive antibody dimerization

Info

Publication number
SG11202112926YA
SG11202112926YA SG11202112926YA SG11202112926YA SG11202112926YA SG 11202112926Y A SG11202112926Y A SG 11202112926YA SG 11202112926Y A SG11202112926Y A SG 11202112926YA SG 11202112926Y A SG11202112926Y A SG 11202112926YA SG 11202112926Y A SG11202112926Y A SG 11202112926YA
Authority
SG
Singapore
Prior art keywords
engineering
hinge region
antibody dimerization
drive antibody
drive
Prior art date
Application number
SG11202112926YA
Inventor
Fernando Garces
Zhulun Wang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11202112926YA publication Critical patent/SG11202112926YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG11202112926YA 2019-05-30 2020-05-29 Engineering the hinge region to drive antibody dimerization SG11202112926YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962854907P 2019-05-30 2019-05-30
PCT/US2020/035196 WO2020243477A2 (en) 2019-05-30 2020-05-29 Engineering the hinge region to drive antibody dimerization

Publications (1)

Publication Number Publication Date
SG11202112926YA true SG11202112926YA (en) 2021-12-30

Family

ID=72234906

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112926YA SG11202112926YA (en) 2019-05-30 2020-05-29 Engineering the hinge region to drive antibody dimerization

Country Status (12)

Country Link
US (1) US20220235148A1 (en)
EP (1) EP3976643A2 (en)
JP (2) JP7500619B2 (en)
KR (1) KR20220016139A (en)
CN (1) CN114174344A (en)
AU (1) AU2020283890A1 (en)
CA (1) CA3141690A1 (en)
EA (1) EA202193322A1 (en)
MX (1) MX2021014534A (en)
SG (1) SG11202112926YA (en)
TW (1) TW202110877A (en)
WO (1) WO2020243477A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024017371A1 (en) * 2022-07-22 2024-01-25 信达生物制药(苏州)有限公司 Mutant promoting homologous pairing of heavy and light chains of multispecific antibody
WO2024209441A1 (en) * 2023-04-07 2024-10-10 Medimmune, Llc Trispecific engineered antibodies

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
DE68925971T2 (en) 1988-09-23 1996-09-05 Cetus Oncology Corp CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
ATE356869T1 (en) 1990-01-12 2007-04-15 Amgen Fremont Inc FORMATION OF XENOGENE ANTIBODIES
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2111348A1 (en) 1991-06-14 1992-12-23 John S. Logan Production of human hemoglobin in transgenic pigs
JPH06508880A (en) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト Thermotropic liquid crystal segmented block copolymer
DK1136556T3 (en) 1991-11-25 2005-10-03 Enzon Inc Process for the preparation of multivalent antigen-binding proteins
JPH07509137A (en) 1992-07-24 1995-10-12 セル　ジェネシス，インク． Production of xenoantibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
JP4046354B2 (en) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Immunoglobulin-like domain with increased half-life
PT1500329E (en) 1996-12-03 2012-06-18 Amgen Fremont Inc Human antibodies that specifically bind human tnf alpha
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd Method of constructing camel antibody library
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101516823B1 (en) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 Stabilized polypeptide compositions
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
CN104497143B (en) 2007-03-29 2020-08-25 健玛保 Bispecific antibody and method for producing same
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
CN101849001B (en) 2007-06-25 2014-07-16 艾斯巴技术-诺华有限责任公司 Methods of modifying antibodies, and modified antibodies with improved functional properties
KR101431318B1 (en) 2009-04-02 2014-08-20 로슈 글리카트 아게 Multispecific antibodies comprising full length antibodies and single chain fab fragments
EA201201435A1 (en) 2010-04-20 2013-04-30 Генмаб А/С HETERODIMERNY ANTIBODY-Fc-CONTAINING PROTEINS AND METHODS FOR THEIR RECEIVING
WO2011143545A1 (en) * 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
US9862769B2 (en) 2010-05-27 2018-01-09 Genmab A/S Monoclonal antibodies against HER2
US10344050B2 (en) 2011-10-27 2019-07-09 Genmab A/S Production of heterodimeric proteins
BR112015029788B1 (en) * 2013-05-31 2024-01-02 Zymeworks Inc HETERO-MULTIMER, USE AND METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND METHOD FOR REDUCING EFFECTOR FUNCTION OF AN IgG FC CONSTRUCT
PT3027642T (en) 2013-07-31 2020-10-30 Amgen Inc Growth differentiation factor 15 (gdf-15) constructs
EP3143043B1 (en) 2014-05-16 2022-12-14 Pfizer Inc. Bispecific antibodies with engineered ch1-cl interfaces
WO2018030806A1 (en) 2016-08-10 2018-02-15 아주대학교산학협력단 Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same

Also Published As

Publication number Publication date
JP2024113040A (en) 2024-08-21
KR20220016139A (en) 2022-02-08
JP2022534901A (en) 2022-08-04
TW202110877A (en) 2021-03-16
EA202193322A1 (en) 2022-03-10
WO2020243477A2 (en) 2020-12-03
CN114174344A (en) 2022-03-11
EP3976643A2 (en) 2022-04-06
CA3141690A1 (en) 2020-12-03
US20220235148A1 (en) 2022-07-28
MX2021014534A (en) 2022-02-11
AU2020283890A1 (en) 2021-12-16
WO2020243477A3 (en) 2021-01-07
JP7500619B2 (en) 2024-06-17

Similar Documents

Publication Publication Date Title
SG11202106214YA (en) Novel anti-ccr8 antibody
EP3556773A4 (en) Anti-human cd73 antibody
EP3662663A4 (en) Intra merge prediction
SG11202108141VA (en) Novel cd40-binding antibodies
IL289112A (en) Anti-tigit antibodies
IL291068A (en) Anti-cd73 antibodies
EP3626745A4 (en) Recombinant bispecific antibody
EP3681788A4 (en) Track drive
IL284584A (en) Anti-tigit antibodies
GB2581174B (en) Antibodies against hEPCR
GB201905150D0 (en) Ant-ige antibodies
EP3768724A4 (en) Novel anti-pd-1 antibodies
ZA202108836B (en) Anti-epha4 antibody
EP4083211A4 (en) Anti-cdcp1 antibody
SG11202112926YA (en) Engineering the hinge region to drive antibody dimerization
GB201900732D0 (en) Antibodies
GB201917480D0 (en) Antibodies
IL289160A (en) Anti-angpt2 antibodies
PL3757334T3 (en) Drive
PL3725992T3 (en) Drive
GB201919062D0 (en) Antibody
EP3911845C0 (en) Harmonic drive
GB2598698B (en) Affinity-maturated anti-ASICIa antibodies
GB201912525D0 (en) Drive assembly
EP3816289A4 (en) Novel anti-pad2 antibody